Genetic and Biomarker Testing for Neurodegenerative Disease - Medicare Advantage

This policy addresses genetic and biomarker testing for neurodegenerative diseases — including SOD1 testing for ALS (relevant to tofersen), genetic evaluation for Alzheimer disease (including APP/PSEN1/PSEN2 and APOE and plasma/blood biomarkers such as PrecivityAD), and assessment of mild cognitive impairment, dementia, and Parkinson disease. The excerpt includes no explicit Medicare coverage decision, frequency or age limits; testing is often tied to therapy‑specific indications and is subject to MolDX/CMS LCD requirements, billing/coding rules, and the regulatory status of tests (FDA‑cleared vs LDTs), which must be consulted for definitive coverage and prior‑authorization requirements.

"Biomarkers Overview | L35062"

Sign up to see full coverage criteria, indications, and limitations.